Gain‐of‐function (GOF) mutations in the PCSK9 gene account for 1% of reported FH cases, such mutations increase the destruction of LDLR on the hepatocyte surface and accordingly result in an increase in levels of circulating LDL‐C.3 Here, PCSK9 is linked to familial hyperaldosteronism.